The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749
Source: Acta Haematologica - Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
More News: Hematology | Iron | Israel Health | Myelodysplastic Syndrome | Statistics | Study | Toxicology